ESSA Pharma (EPIX) Stock Analysis

What ESSA Pharma does

ESSA Pharma Inc. (EPIX) functions as a clinical-stage pharmaceutical firm, concentrating its efforts on developing innovative and exclusive therapies designed to combat prostate cancer. The company's primary drug candidate is EPI-7386, an oral treatment presently undergoing Phase I clinical trials. This investigational compound is intended for individuals suffering from metastatic castration-resistant prostate cancer. Furthermore, ESSA Pharma has established collaborative partnerships with organizations including Caris Life Sciences, Inc., Bayer Consumer Care AG, Janssen Research & Development, LLC, and Astellas Pharma Inc. Founded in 2009, the company's corporate offices are located in Vancouver, Canada.

Key metrics

ETFs linked to EPIX

Broad-market and Healthcare sector ETFs an investor holding ESSA Pharma is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how EPIX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for ESSA Pharma?

ESSA Pharma trades under the ticker EPIX on NASDAQ.

Which exchange is EPIX listed on?

EPIX is listed on NASDAQ.

What sector does ESSA Pharma operate in?

ESSA Pharma is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze EPIX in a portfolio?

PortView shows EPIX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.